跳至主要内容
临床试验/JPRN-jRCT2031220583
JPRN-jRCT2031220583进行中(未招募)1 期

A Phase 1 clinical study of nemtabrutinib (MK-1026) in Japanese participants with hematological malignancies (BELLWAVE-002)

Koh Yasuhiro0 个研究点目标入组 12 人开始时间: 2023年1月22日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable(—)
性别
All

入选标准

  • Histologically confirmed B-cell malignancy:
  • *Chronic lymphocytic leukemia (CLL)
  • *Small lymphocytic lymphoma (SLL)
  • *Waldenstrom's macroglobulinemia (WM)
  • *Lymphoplasmacytic lymphoma (LPL)
  • *Other B-cell neoplasm
  • - Failed or intolerant to either at least 2 prior regimens given in combination or sequentially OR have received 1 prior Bruton's tyrosine kinase (BTK)-containing regimen when a BTK inhibitor is approved as first line therapy
  • - Have the ability to swallow and retain oral medication
  • - Is Japanese

排除标准

  • - Active Hepatitis B virus (HBV)/Hepatitis C virus (HCV) infection at study entry
  • - History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years
  • - Known history of human immunodeficiency virus (HIV) infection
  • - Clinically significant gastrointestinal abnormalities that might alter absorption (eg, gastric bypass surgery,gastrectomy)
  • - Underlying history of severe bleeding disorders
  • - History or concurrent condition of pneumonitis/interstitial lung disease

研究者

发起方
Koh Yasuhiro

相似试验

已完成
1 期
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)Mature B-cell Neoplasms
NCT05673460Merck Sharp & Dohme LLC7
招募中
2 期
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell LymphomaMantle Cell Lymphoma
NCT06572618City of Hope Medical Center27
进行中(未招募)
1 期
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
EUCTR2015-003656-40-GBPharmacyclics LLC308
进行中(未招募)
不适用
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary TumorsMetastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)MedDRA version: 18.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003656-40-ESPharmacyclics LLC189
进行中(未招募)
1 期
Ibrutinib in relapsed lymphocyte-predominant Hodgkin lymphoma
EUCTR2015-003128-30-DEniversity of Cologne36